SERB acquired by CHARTERHOUSE

Théradial has completed a shareholder restructuring agreement, welcoming UI Gestion and Bpifrance as new majority shareholders. This transaction is part of a management buy-out, enabling Frédéric Le Pottier, the former Commercial Director, to take the helm as Chairman of the Executive Board. Meanwhile, Bruno Duval, the company's founder, will retain a key role as a shareholder and become Chairman of the Supervisory Board. The goal of this transaction is to support Théradial's growth strategy, which aims to leverage its pharmaceutical establishment status, obtained two years ago, to expand its product portfolio

Fresenius Medical Care announced a definitive agreement to acquire all outstanding shares of NxStage Medical. The acquisition is strategically central to FMC's 2020 strategic initiative, positioning the combined entity as a global leader in home dialysis by integrating NxStage's System One platform into FMC's vertically integrated dialysis ecosystem. The transaction is expected to generate net cost synergies of approximately $80–100 million per annum before tax over three to five years, with integration costs of approximately $150 million over the first three years

EQT VII has entered into an agreement to acquire a 20% minority stake in Ottobock, as part of a strategic partnership aimed at supporting Ottobock's international growth ambitions, driving its strategic objectives, and potentially preparing the company for a future initial public offering (IPO) in the medium term. The investment by EQT comes at a time of significant transformation in the mobility technology market, driven by an aging population, increasing demand for rehabilitation solutions, and advancements in smart prosthetics

Orchestrating a major shift in the European medtech landscape, this majority buyout extracts ELITechGroup from its previous financial framework to catalyze an aggressive international scaling phase. The strategic rationale centers on leveraging the target's specialized molecular diagnostic footprint to navigate the maturing global healthcare sector. Rather than a simple portfolio addition, this move represents a calculated bet on the structural transition toward decentralized laboratory automation and precision pathology

The Executive Board and Supervisory Board of STADA agreed to support a voluntary public tender offer from Bain Capital and Cinven. The offer of EUR66.00 per share (including dividend) values the company at an Enterprise Value of approximately EUR5.318 billion. This price represents a premium of roughly 49% over the unaffected share price from December 2016. The deal concludes a highly competitive bidding process (where Advent International was also a contender). The strategic rationale is to delist STADA to allow for a more aggressive long-term growth strategy, unburdened by quarterly public reporting

The acquisition of Vention Advanced Technologies by Nordson Corporation signifies a major step in the group’s expansion into the high-growth medtech sector. The strategic logic of this transaction hinges on a "market-balancing" maneuver, merging the target’s industry-leading technical operational depth in interventional delivery systems with the buyer’s established scale in precision fluid management. This alignment equips the combined organization with the scientific talent and manufacturing hardware necessary to address the increasing demand for minimally invasive medical solutions across North America, Europe, and Asia

Ardian, an independent private investment firm, has entered into exclusive negotiations to acquire a majority stake in Unither Pharmaceuticals, a global leader in the Contract Development and Manufacturing Organization (CDMO) sector. Ardian submitted a firm offer to Equistone, which leads a consortium of sellers including historical shareholders Parquest Capital and CM-CIC Investissement.

Ecolab has completed the acquisition of 100% of Laboratoires Anios from Ardian and the Letartre family. This transaction represents a definitive exit for the private equity firm Ardian, which had supported the founding family in a 2013 LBO following a previous ownership cycle by Air Liquide. The strategic rationale for Ecolab is to establish a dominant foothold in the European hospital disinfection market, a segment where it was previously underrepresented. For Anios, the merger provides a global springboard, particularly to accelerate its expansion into the Chinese market

Ardian entered into exclusive negotiations to acquire a majority stake in Lagarrigue from Azulis Capital. The transaction allowed the management team to reinforce their equity stake. Historical minority investor iXO Private Equity reinvested, while Azulis Capital, Galia Gestion, and BNP Paribas Developpement fully exited. This deal marked the transition from a regional SME to a national leader with international ambitions. The roadmap focused on external growth and digital transformation.

On September 19, 2016, ArchiMed completed the acquisition of a majority stake in Polyplus Transfection, a prominent player in the biologics delivery space. The transaction was executed as a proprietary deal, seamlessly completed outside of any formal auction process, and was heavily supported by the existing management team. This strategic move represents a textbook platform investment for the private equity firm, executed through its Med 1 fund, capitalizing on their deep sector expertise. The strategic rationale behind this transaction is deeply rooted in the strong secular growth currently observed across biologics-based therapeutics and cell therapies